ClinicalTrials.gg
RecruitingNCT06798012CASCAUpdated Nov 3, 2026

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Phase 2 interventional study of TAK-411 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), sponsored by Takeda. Recruiting at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 3, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
30th of 42
36 · median 74
Started
2025
with 12 others
Phase 2
16 of 55
2 open now
Primary completion
2027-12
later than 12 of 24 live
Registered
43rd of 55
by date
Lead sponsor
4 of 55
Takeda

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 30th largest by planned enrollment of the 42 interventional ones that give a count, is one of 13 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 12 of the 24 other live ones, and was the 43rd registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG).

TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP.

The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial.

Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose.

During the study, participants may visit their study clinic up to approximately 21 times.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. The participant is at least 18 years of age, inclusive, at the time of signing the Form (ICF).
  2. The participant has a body weight of less than or equal to (\<=) 150 kilogram (kg).
  3. The participant has a documented diagnosis of typical CIDP, as confirmed by a neurologist specializing/experienced in neuromuscular diseases and consistent with the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021 criteria.
  4. The participant has responded to IgG treatment in the past (documented partial or complete resolution of neurological symptoms and deficits).
  5. The participant has had disease activation within 24 months before screening, as documented in medical records and in the opinion of the investigator, defined as one of the following:

    1. deterioration of symptoms on interruption or dose reduction of IgG treatment.
    2. Clinically meaningful deterioration of symptoms requiring IgG treatment dose increase with subsequent clinical improvement.
    3. Clinically meaningful deterioration of symptoms at the end of IgG treatment dose interval with improvement after next dose administration.
  6. The participant is on a stable dose of immunoglobulin treatment intravenously (IGIV) treatment, (within the dose range of 0.4 to 2.4 grams per kilogram [g/kg] every 2 to 6 weeks [inclusive]). A stable dose is defined as no change greater than 10 percentage (%) in frequency or dose of IGIV therapy within the 3 months before and throughout screening.
  7. The participant has an INCAT score between 0 and 7 (inclusive) at screening.

Key Exclusion Criteria

  1. The participant has a documented diagnosis of a CIDP variant per EAN/PNS 2021 criteria.
  2. The participant has any neuropathy of other causes, including the following:

    1. Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy, Charcot-Marie-Tooth disease, and hereditary sensory and autonomic neuropathies.
    2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and nondiabetic lumbosacral radiculoplexus neuropathy, lymphoma, amyloidosis.
    3. Multifocal motor neuropathy.
    4. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy.
    5. Diabetic peripheral neuropathy.
  3. The participant has any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or that may interfere with assessment of CIDP or outcome measures, including (but not limited to) multiple sclerosis, arthritis, stroke, and Parkinson's disease.
  4. The participant is required to take or has taken either of the following for treatment of CIDP:

    1. Immunomodulatory/ agents (except IGIV) that include, but are not limited to, complement inhibitors, efgartigimod, and chemotherapeutic drugs, within 3 months or 5 half-lives, whichever is longer, of screening.
    2. B-cell affecting biologics (e.g. rituximab) within 6 months of screening.

    Note: Participants on a long-term, stable dosing regimen of certain immunomodulatory agents (eg, hydroxychloroquine) for any disease other than CIDP may be eligible, provided the dose regimen has been stable for 3 months before screening and is expected to remain stable throughout the study.

  5. The participant has undergone plasma exchange within 3 months of screening.
  6. The participant has a history of with less than 2 years of complete remission before screening, or active malignancy requiring chemotherapy and/or radiotherapy.

    Note: Participants with adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment are eligible.

  7. The participant has experienced deep vein thrombosis or arterial thromboembolic events (example, cerebrovascular accident, pulmonary embolism) within 12 months of screening.
  8. The participant has any medical condition, laboratory finding, or physical examination finding that precludes participation or with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the study or place the participant at undue medical risk.
  9. The participant has participated in another clinical study involving an IP or device within 30 days before screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    TAK-411

    Participants will receive TAK-411 400 milligrams per kilogram (mg/kg), IV infusion as an induction dose on Day 1 of initial treatment period. The induction dose may be repeated once after 3 weeks if participants exhibit no clinical change. Thereafter, participants will receive TAK-411 200 mg/kg, IV infusion every 3 weeks for a total of 24 weeks (initial treatment period), followed by an optional additional 27 weeks (extended treatment period).

    Biological: TAK-411

Interventions

  • BiologicalTAK-411

    TAK-411 IV infusion.

    Also known as: Hypersialylated Immune Globulin G

06

What researchers measure

Primary outcomes

  1. Number of Participants With Improvement in Functional Ability at Week 24

    Improvement in functional ability is defined as decrease of \>=1 point in INCAT score at Week 24 compared with baseline (last assessment before first investigational product \[IP\] administration on Day 1). INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded.

    Time frame: At Week 24

Secondary outcomes

  1. Number of Participants With Improvement in Functional Ability at Weeks 12 and 54

    Improvement in functional ability is defined as decrease of \>=1 point in the adjusted INCAT score at 12 and 54 weeks compared with baseline (last assessment before first IP administration on Day 1). INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded.

    Time frame: At 12 and 54 weeks

  2. Change From Baseline in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Score

    INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded.

    Time frame: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks

  3. Change From Screening in the Adjusted INCAT Score

    INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded.

    Time frame: Screening, at 12, 24 and 54 weeks

  4. Number of Participants With Improvement in Functional Ability on Inflammatory Rasch-built Overall Disability Scale (I-RODS) Score

    Improvement in functional ability defined as increase of greater than or equal to (\>=) 4 points in the raw summed I-RODS score at 12, 24, and 54 weeks compared with baseline. I-RODS is a validated, participants-reported, linearly weighted overall disability scale that was specifically designed to capture current activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. I-RODS comprises 24 items for which participants are asked to rate their functioning related to a variety of everyday tasks at the moment of completion. The participant assigns a score between 0 and 2 to each item as follows:0 (impossible to perform),1 (performed with difficulty), 2 (easily performed) with a lower score indicating more severe activity and social participation limitations. A total I-RODS score of 0 (complete disability) to 48 (no disability) is tabulated by totalling the 24-item responses where higher score represents better outcomes.

    Time frame: At 12, 24 and 54 weeks

  5. Change From Baseline in I-RODS Score

    The I-RODS is a validated, participants-reported, linearly weighted overall disability scale that was specifically designed to capture current activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. The I-RODS comprises 24 items for which participants are asked to rate their functioning related to a variety of everyday tasks at the moment of completion. The participant assigns a score between 0 and 2 to each item as follows: 0 (impossible to perform), 1 (performed with difficulty), 2 (easily performed) with a lower score indicating more severe activity and social participation limitations. A total I-RODS score of 0 (complete disability) to 48 (no disability) is tabulated by totalling the 24-item responses where higher score represents better outcomes.

    Time frame: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks

  6. Change From Screening in I-RODS Score

    The I-RODS is a validated, participants-reported, linearly weighted overall disability scale that was specifically designed to capture current activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. The I-RODS comprises 24 items for which participants are asked to rate their functioning related to a variety of everyday tasks at the moment of completion. The participant assigns a score between 0 and 2 to each item as follows: 0 (impossible to perform), 1 (performed with difficulty), 2 (easily performed) with a lower score indicating more severe activity and social participation limitations. A total I-RODS score of 0 (complete disability) to 48 (no disability) is tabulated by totalling the 24-item responses where higher score represents better outcomes.

    Time frame: Screening, at 12, 24 and 54 weeks

  7. Change From Baseline in Medical Research Council Sum Score (MRC-SS)

    The MRC-SS is used clinician-reported measure of muscle strength. Assessments are conducted bilaterally on six muscle groups: upper arm abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and foot dorsal flexors. Each muscle is rated from 0 to 5, where 0 indicates no visible contraction and 5 indicates normal strength. The scores are summed to obtain the MRC-SS, which ranges from 0 (quadriplegic) to 60 (normal strength).

    Time frame: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks

  8. Change From Screening in MRC-SS

    The MRC-SS is used clinician-reported measure of muscle strength. Assessments are conducted bilaterally on six muscle groups: upper arm abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and foot dorsal flexors. Each muscle is rated from 0 to 5, where 0 indicates no visible contraction and 5 indicates normal strength. The scores are summed to obtain the MRC-SS, which ranges from 0 (quadriplegic) to 60 (normal strength).

    Time frame: Screening, at 12, 24 and 54 weeks

  9. Change From Baseline in Bilateral Hand Grip Strength

    Bilateral hand grip strength assessments will be performed by prescribing physicians or qualified designees using the Martin Vigorimeter, measuring strength in kilopascals (kPa) ranging from 0 to 160 kPa.

    Time frame: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks

  10. Change From Screening in Bilateral Grip Strength

    Bilateral hand grip strength assessments will be performed by prescribing physicians or qualified designees using the Martin Vigorimeter, measuring strength in kPa ranging from 0 to 160 kPa.

    Time frame: Screening, at 12, 24 and 54 weeks

  11. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: From start of study drug administration up to 54 weeks

  12. Number of Participants With Infusion Discontinuations, Interruptions, and Infusion Rate Reductions due to TAK-411 Related TEAEs

    Time frame: From start of study drug administration up to 54 weeks

  13. Number of Participants With Antibodies Against Host Cell Proteins (HCP), Beta-1,4-galactosyltransferase (B4GalT1) and Alpha-2,6-sialyltransferase (St6Gal1)

    Time frame: Up to 54 weeks

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
May 14, 2025
Primary completionEst.
Dec 2, 2027
CompletionEst.
Jun 8, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • University of Calgary · Calgary, CanadaNot yet recruiting→Recruiting
  • University Health Network · Toronto, CanadaNot yet recruiting→Recruiting
  • Neuro ClinicaS.A.S · Medellín, ColombiaNot yet recruiting→Recruiting
  • Hospital Universitario San Ignacio · Bogotá, ColombiaNot yet recruiting→Recruiting
  • Fundacion Valle del Lili · Cali, ColombiaNot yet recruiting→Recruiting
  • Universidad del Rosario · Bogotá, ColombiaNot yet recruiting→Recruiting
  • Fundacion Oftalmologica de Santander - FOSCAL · Bucaramanga, ColombiaNot yet recruiting→Recruiting
Show 3 added (3 United States)
  • MedStar Georgetown University Hospital · Washington D.C., United States
  • Knight Neurology · Rockledge, United States
  • Velocity Clinical Research - Raleigh · Raleigh, United States
Show 1 removed
  • Houston Methodist Research Institute · Houston, United States
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University Health Network · Toronto, CanadaContact person changed (no phone or email listed)Contact •••3315→•••3662Contact v•••@utoronto.ca→h•••@uhn.ca
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    3 sites added, 1 site removed. 7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • University of Calgary · Calgary, CanadaNot yet recruiting→Recruiting
    • University Health Network · Toronto, CanadaNot yet recruiting→Recruiting
    • Neuro ClinicaS.A.S · Medellín, ColombiaNot yet recruiting→Recruiting
    • Hospital Universitario San Ignacio · Bogotá, ColombiaNot yet recruiting→Recruiting
    • Fundacion Valle del Lili · Cali, ColombiaNot yet recruiting→Recruiting
    • Universidad del Rosario · Bogotá, ColombiaNot yet recruiting→Recruiting
    • Fundacion Oftalmologica de Santander - FOSCAL · Bucaramanga, ColombiaNot yet recruiting→Recruiting
    Show 3 added (3 United States)
    • MedStar Georgetown University Hospital · Washington D.C., United States
    • Knight Neurology · Rockledge, United States
    • Velocity Clinical Research - Raleigh · Raleigh, United States
    Show 1 removed
    • Houston Methodist Research Institute · Houston, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University Health Network · Toronto, CanadaContact person changed (no phone or email listed)Contact •••3315→•••3662Contact v•••@utoronto.ca→h•••@uhn.ca
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06798012
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
May 14, 2025
Primary completion
Dec 2, 2027 (estimated)
Completion
Jun 8, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion